In recent years, researchers' attention drawn to
examining the role of antibodies to phospholipids (APL) in the development of thrombotic disorders and
vascular pathology in systemic lupus erythematosus (SLE). AFL
considered as a heterogeneous population of antibodies reacting with cardiolipin and other negatively charged phospholipids
having the activity of lupus
antinoagulyanta (VA) or cause development of false-positive reactions
Wasserman (LPRV) [1]. Convincingly shown that the products associated with APL
development outlined sufficient symptom, known as
antiphospholipid syndrome (APS), one manifestation of which is
central nervous system. (CNS) [6, 8].

spectasm of neurological disorders associated with the production of APL,
very broad and includes the cerebral circulation (NMC), chorea,
convulsive disorder, migraine headaches, visual disturbances, psychosis, transverse myelitis,
Guillain-Barre syndrome [8]. To date, the literature has accumulated a lot of
data confirming the existence of such a relationship in SLE. However, the majority of works devoted to the description
separate clinical observations or the presence of APL
studied in the general population of SLE patients, which makes up
representation of the tase frequency and spectasm of neurological disorders,
associated with the identification of these antibodies.

The purpose of this study was to identify the relationship
CNS SLE patients with a level kardiolipinzavisimoy